Home | Accelerate@Babraham | Meet the experts | Marcus Yeo

Marcus Yeo

CEO, DefiniGEN

Dr Marcus Yeo is a founder and CEO of DefiniGEN. He is an experienced Company Director and life scientist who took the Oxford-based diagnostics biotechnology company Cybersense Biosystems Ltd to acquisition in 2008 by the FTSE 100 company Severn Trent. He oversaw the integration of the business into the Severn Trent ISO 17025 structure and led sales and marketing of the Severn Trent analytics division. Marcus previously worked for the University of Oxford company Zyoxel Ltd (now CN Bio Innovations), which markets advanced 3D human tissue culture systems to the investigative toxicology drug discovery sector. He specialised in the development of next-generation stem cell derived liver toxicology products and disease modelling systems for drug discovery lead optimisation. He has a PhD in Molecular Biology and is an accredited European Commission Technology Expert who has managed in excess of £15m of R&D funding.

Contact us


(+44) 1223 496 000

Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom

Press Enquiries

01223 813 557

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
; ;